PXR triggers YAP-TEAD binding and Sirt2-driven YAP deacetylation and polyubiquitination to promote liver enlargement and regeneration in mice.

[1]  H. Bi,et al.  Nuclear Receptor-Mediated Hepatomegaly and Liver Regeneration: An Update , 2022, Drug Metabolism and Disposition.

[2]  Ping Li,et al.  PXR activation impairs hepatic glucose metabolism partly via inhibiting the HNF4α–GLUT2 pathway , 2021, Acta pharmaceutica Sinica. B.

[3]  P. Song,et al.  Shear stress–induced cellular senescence blunts liver regeneration through Notch–sirtuin 1–P21/P16 axis , 2021, Hepatology.

[4]  F. Gonzalez,et al.  YAP‐TEAD mediates PPAR α–induced hepatomegaly and liver regeneration in mice , 2021, Hepatology.

[5]  Fei Li,et al.  PXR mediates mifepristone-induced hepatomegaly in mice , 2021, Acta Pharmacologica Sinica.

[6]  J. Baur,et al.  SIRT3 is required for liver regeneration but not for the beneficial effect of nicotinamide riboside , 2021, JCI insight.

[7]  G. Yuan,et al.  Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α , 2021, Hepatology.

[8]  M. Huang,et al.  Schisandrol B promotes liver enlargement via activation of PXR and YAP pathways in mice. , 2021, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[9]  F. Gonzalez,et al.  Constitutive androstane receptor induced-hepatomegaly and liver regeneration is partially via yes-associated protein activation , 2020, Acta pharmaceutica Sinica. B.

[10]  Wenzhou Li,et al.  SIRT6 as a key event linking P53 and NRF2 counteracts APAP-induced hepatotoxicity through inhibiting oxidative stress and promoting hepatocyte proliferation , 2020, Acta pharmaceutica Sinica. B.

[11]  D. Pan,et al.  The Hippo Pathway in Liver Homeostasis and Pathophysiology. , 2020, Annual review of pathology.

[12]  Tong Liu,et al.  Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear Localization and Exacerbates Atherosclerosis. , 2020, Cell reports.

[13]  X. Yang,et al.  Dexamethasone-Induced Liver Enlargement Is Related to PXR/YAP Activation and Lipid Accumulation but Not Hepatocyte Proliferation , 2020, Drug Metabolism and Disposition.

[14]  Shihao Zhang,et al.  Role of the transcriptional coactivators YAP/TAZ in liver cancer. , 2019, Current opinion in cell biology.

[15]  Rongting Huang,et al.  Crosstalk of intracellular post-translational modifications in cancer. , 2019, Archives of biochemistry and biophysics.

[16]  K. Guan,et al.  The Hippo Pathway: Biology and Pathophysiology. , 2019, Annual review of biochemistry.

[17]  Xiaochao Ma,et al.  Pregnane X Receptor Regulates Liver Size and Liver Cell Fate by Yes‐Associated Protein Activation in Mice , 2018, Hepatology.

[18]  Z. Xiang,et al.  The roles of sirtuins family in cell metabolism during tumor development. , 2019, Seminars in cancer biology.

[19]  K. Gevaert,et al.  Protein Language: Post-Translational Modifications Talking to Each Other. , 2018, Trends in plant science.

[20]  Chunaram Choudhary,et al.  Functions and mechanisms of non-histone protein acetylation , 2018, Nature Reviews Molecular Cell Biology.

[21]  Shihao Zhang,et al.  SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis. , 2018, Cancer cell.

[22]  Li Ma,et al.  SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity , 2018, Nature Communications.

[23]  C. Peng,et al.  Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation. , 2017, Molecular cell.

[24]  G. Michalopoulos.  Hepatostat: Liver regeneration and normal liver tissue maintenance , 2017, Hepatology.

[25]  N. Gray,et al.  Pharmacological targeting of kinases MST1 and MST2 augments tissue repair and regeneration , 2016, Science Translational Medicine.

[26]  John M. Asara,et al.  Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth , 2016, Nature Cell Biology.

[27]  Hang Zeng,et al.  Schisandra sphenanthera Extract Facilitates Liver Regeneration after Partial Hepatectomy in Mice , 2016, Drug Metabolism and Disposition.

[28]  John M Denu,et al.  Mechanisms and Dynamics of Protein Acetylation in Mitochondria. , 2016, Trends in biochemical sciences.

[29]  Bin Zhao,et al.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.

[30]  A. Bauer,et al.  YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors , 2015, Hepatology.

[31]  J. Llovet,et al.  YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. , 2015, Cell reports.

[32]  K. Guan,et al.  Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway , 2015, Nature Cell Biology.

[33]  B. Mao,et al.  SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma , 2014, Oncogene.

[34]  Sumit Jain,et al.  Human pregnane X receptor: a novel target for anticancer drug development. , 2014, Drug discovery today.

[35]  M. Sudol,et al.  Structures of YAP protein domains reveal promising targets for development of new cancer drugs. , 2012, Seminars in cell & developmental biology.

[36]  Jean S. Campbell,et al.  Liver regeneration. , 2012, Journal of hepatology.

[37]  Satoko Arakawa,et al.  Hypertrophy and Unconventional Cell Division of Hepatocytes Underlie Liver Regeneration , 2012, Current Biology.

[38]  R. Maronpot,et al.  Liver Hypertrophy , 2012, Toxicologic pathology.

[39]  Y. Hata,et al.  A Novel Acetylation Cycle of Transcription Co-activator Yes-associated Protein That Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating Agents* , 2012, The Journal of Biological Chemistry.

[40]  U. Gat,et al.  The evolutionary history of YAP and the hippo/YAP pathway. , 2011, Molecular biology and evolution.

[41]  S. Hill,et al.  Journal of Steroid Biochemistry and Molecular Biology the Pxr Is a Drug Target for Chronic Inflammatory Liver Disease , 2022 .

[42]  D. Sinclair,et al.  Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.

[43]  John Rush,et al.  Quantitative Proteomics Reveals the Function of Unconventional Ubiquitin Chains in Proteasomal Degradation , 2009, Cell.

[44]  D. Cowie,et al.  A mechanism for the anti-fibrogenic effects of the pregnane X receptor (PXR) in the liver: inhibition of NF-kappaB? , 2008, Toxicology.

[45]  Jie Zhou,et al.  PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. , 2008, Molecular pharmaceutics.

[46]  Daniela Hoeller,et al.  Ubiquitin and ubiquitin-like proteins in cancer pathogenesis , 2006, Nature Reviews Cancer.

[47]  W. S. Baldwin,et al.  CAR and PXR: xenosensors of endocrine disrupters? , 2005, Chemico-biological interactions.

[48]  T. Willson,et al.  Pxr, car and drug metabolism , 2002, Nature Reviews Drug Discovery.

[49]  T. Willson,et al.  Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. , 2002, Journal of lipid research.

[50]  M. Sudol,et al.  Yes-associated Protein and p53-binding Protein-2 Interact through Their WW and SH3 Domains* , 2001, The Journal of Biological Chemistry.

[51]  T. Willson,et al.  The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  K. Jungermann,et al.  Functional specialization of different hepatocyte populations. , 1989, Physiological reviews.